Article

The suppression of malarial parasitaemia by pyrimethamine in combination with dapsone or sulphormethoxine.

Departments of Preventive and Social Medicine, Paediatrics and Medical Microbiology and the Institute of Child Health, University of Ibadan, and the Wellcome Laboratories of Tropical Medicine, Beckenham, Kent, UK
Transactions of the Royal Society of Tropical Medicine and Hygiene (Impact Factor: 1.93). 02/1969; 63(2):216-29. DOI: 10.1016/0035-9203(69)90150-3
Source: PubMed

ABSTRACT The antimalarial activity of pyrimethamine in combination either with dapsone or with sulphormethoxine, was compared with that of pyrimethamine alone. In this double-blind controlled study, 280 children, living in an area of stable P. falciparum malaria, were observed during one year. With pyrimethamine alone there was incomplete suppression of parasitaemia with crude parasite rates ranging from 2 to 25%. The first dose of the drug combinations produced a rapid clearance of parasitaemia, and weekly administration of the drug combinations sustained a virtually complete suppression of parasitaemia throughout the year. The drugs were well tolerated and no serious side-effects were encountered among the treated children.

0 Bookmarks
 · 
50 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: In malaria endemic areas, pre-school children are at high risk of severe and repeated malaria illness. One possible public health strategy, known as Intermittent Preventive Treatment in children (IPTc), is to treat all children for malaria at regular intervals during the transmission season, regardless of whether they are infected or not. To evaluate the effects of IPTc to prevent malaria in preschool children living in endemic areas with seasonal malaria transmission. We searched the Cochrane Infectious Diseases Group Specialized Register (July 2011), CENTRAL (The Cochrane Library 2011, Issue 6), MEDLINE (1966 to July 2011), EMBASE (1974 to July 2011), LILACS (1982 to July 2011), mRCT (July 2011), and reference lists of identified trials. We also contacted researchers working in the field for unpublished and ongoing trials. Individually randomized and cluster-randomized controlled trials of full therapeutic dose of antimalarial or antimalarial drug combinations given at regular intervals compared with placebo or no preventive treatment in children aged six years or less living in an area with seasonal malaria transmission. Two authors independently assessed eligibility, extracted data and assessed the risk of bias in the trials. Data were meta-analysed and measures of effects (ie rate ratio, risk ratio and mean difference) are presented with 95% confidence intervals (CIs). The quality of evidence was assessed using the GRADE methods. Seven trials (12,589 participants), including one cluster-randomized trial, met the inclusion criteria. All were conducted in West Africa, and six of seven trials were restricted to children aged less than 5 years.IPTc prevents approximately three quarters of all clinical malaria episodes (rate ratio 0.26; 95% CI 0.17 to 0.38; 9321 participants, six trials, high quality evidence), and a similar proportion of severe malaria episodes (rate ratio 0.27, 95% CI 0.10 to 0.76; 5964 participants, two trials, high quality evidence). These effects remain present even where insecticide treated net (ITN) usage is high (two trials, 5964 participants, high quality evidence).IPTc probably produces a small reduction in all-cause mortality consistent with the effect on severe malaria, but the trials were underpowered to reach statistical significance (risk ratio 0.66, 95% CI 0.31 to 1.39, moderate quality evidence).The effect on anaemia varied between studies, but the risk of moderately severe anaemia is probably lower with IPTc (risk ratio 0.71, 95% CI 0.52 to 0.98; 8805 participants, five trials, moderate quality evidence).Serious drug-related adverse events, if they occur, are probably rare, with none reported in the six trials (9533 participants, six trials, moderate quality evidence). Amodiaquine plus sulphadoxine-pyrimethamine is the most studied drug combination for seasonal chemoprevention. Although effective, it causes increased vomiting in this age-group (risk ratio 2.78, 95% CI 2.31 to 3.35; two trials, 3544 participants, high quality evidence).When antimalarial IPTc was stopped, no rebound increase in malaria was observed in the three trials which continued follow-up for one season after IPTc. In areas with seasonal malaria transmission, giving antimalarial drugs to preschool children (age < 6 years) as IPTc during the malaria transmission season markedly reduces episodes of clinical malaria, including severe malaria. This benefit occurs even in areas where insecticide treated net usage is high.
    Cochrane database of systematic reviews (Online) 01/2012; 2(2):CD003756. DOI:10.1002/14651858.CD003756.pub4 · 5.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: ECENT years have witnessed a phenomenal increase in the production in Nigeria, of a rich dark liquid which has added a new dimension to the lives of millions of Nigerians. The gleaming installations from which this liquid flows have become symbols of happiness in the present and unending hope for the future. Irishmen will appreciate my meaning, when I say that I am referreing, not to Nigeria's new oil wealth, but to that other liquid which throughout the country is proclaimed "DRINK GUINNESS FOR POWER". Were this the only bond between the countries, it would have been enough to cement everlasting friendship. There are however many other bonds, and none stronger than those that bind the medical fraternity in the two countries. Go where you will in Nigeria, from the smallest villages to the largest cities, from the humblest mission hospitals to the proudest university hospitals, and there you will find men and women who owe much to the people of this country and its academic institutions. Ireland in general, and Dublin in particular, has made a tremendous contribution to medical services and medical education in Nigeria, and it was fitting indeed that the first Minister of Health in the first independent Nigerian government was a graduate of Dublin. With these thoughts in mincl and in terms of my own deep personal invo',vement in the affairs of Nigeria, I am very pleased, and feel very greatly honoured indeed, to have the privilege of addressing the Royal Irish Academy of Medicine on this occasion. I thank you for the privilege and trust that I may prove worthy of the honour. Before proceeding with my account of various aspects of Paediatrics in Nigeria, I would like to pay tribute to a friend and colleague who has added his special contribution to medical development in Nigeria. I refer to Professor W. R. F. Collis. Bob Collis arrived in Nigeria in 1957 and, like a rugby player caught up in an international match, proceeded to tackle the problems of child health, with an enthusiasm never seen before, and as yet unsurpassed. In the process, he broke a few noses, dislocated a few hips and bruised a few glutei in the ranks of the civil service, the universities and among medical traditionalists, but in so doing he gave hope to millions that the future would have more promise for their children than the past. His rumbustuous path down the corridors of power in the new Nigeria, left no doors closed if opening them meant something for the welfare of children. It is a tribute to him that Nigeria decided to use a generous independence gift donated by the United Africa Company to set up institutes of child health in major centres in Nigeria. If this was the only thing he did, it would have been enough, but it was only the beginning. In the years that followed he contributed to the development of paediatrics and child health at the Universities of Ibadan, Lagos and Zaria successively, and through his writings he assisted in focusing world attention on the people of Nigeria,
    Irish Journal of Medical Science 10/1971; 140(10):460-470. DOI:10.1007/BF02940116 · 0.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cycloguanil pamoate in an oleaginous suspension was injected into the deep muscle of the buttocks of 10 older children and adults in Ilora, Western State of Nigeria. The suspension and the injection were not resented. Only mild reactions of tenderness and pain lasting about 2 days were noted. The oleaginous suspension as at present constituted is too thick for a quick and comfortable injection.The effectiveness of a single injection of cycloguanil pamoate, combined with a one-dose treatment with chloroquine phosphate was tested in a group of semi-immune African school children aged 6–10 years in a holoendemic malaria region.The curative effect of the drug combination was demonstrated in 93% one week after treatment, and it persisted to about the end of the 6th week. Thereafter, reinfection appeared in 29·0% of the protected group before the 12th week, and in the 18th week asexual malaria parasitaemia had become re-established in over two-thirds of the children. Only 22 of 114 children examined had remained completely free of asexual parasitaemia for up to the 18th week. The dose of cycloguanil used per child ranged from 7·3 mg. to 10·8 mg per kg. of body weight. Chloroquine phosphate in a single oral dose as recommended by the W.H.O. was nearly as effective as the drug combination up to the 6th week.There was evidence of more cases of heavy parasitaemia in the treated children who became reinfected only after 10 weeks of freedom from malaria parasitaemia than in the untreated controls, which suggests that in rural Nigerian school children aged 6–10 years, the immunological ability to suppress malaria parasitaemia very largely depends on the actual and uninterrupted presence of malaria parasites. That the antiparasitic immunity to malaria in this age group studied could be so delicate and capable of being eliminated inside 12 weeks of freedom from parasitaemia is an unexpected finding in the holoendemic malarious region of Nigeria.
    Transactions of the Royal Society of Tropical Medicine and Hygiene 01/1970; 64(6):839-49. DOI:10.1016/0035-9203(70)90103-3 · 1.93 Impact Factor